Ranbaxy battles growing regulatory concern in India and abroad
This article was originally published in Scrip
Executive Summary
Ranbaxy Laboratories appears to be trudging along on a wing and prayer, given the crescendo of regulatory voices, including those of the Drugs Controller General of India (DCGI) and the European Medicines Agency that have flagged up concerns over the string of good manufacturing practice (GMP) deviations at its Indian sites including the recently barred active pharmaceutical ingredients (API) facility in Toansa.